Clinical Trial Update: Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating safety and efficacy of rFIXFc in previously untreated males with severe Hemophilia B has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rFIXFc (recombinant Factor IX Fc fusion protein)

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2020-07-31